Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: A focus group study.

van Leeuwen NM, Boonstra M, Huizinga TWJ, Kaptein AA, de Vries-Bouwstra JK.

Musculoskeletal Care. 2020 Jan 26. doi: 10.1002/msc.1453. [Epub ahead of print]

PMID:
31984643
2.

Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.

Ciaffi J, van Leeuwen NM, Liem SIE, Ninaber MK, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Rheumatol. 2020 Jan 24. doi: 10.1007/s10067-020-04951-6. [Epub ahead of print]

PMID:
31980971
3.

The contribution of sex and auto-antibodies to microangiopathy assessed by nailfold videocapillaroscopy in systemic sclerosis: a systematic review of the literature.

van Leeuwen NM, Ciaffi J, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK.

Arthritis Care Res (Hoboken). 2020 Jan 21. doi: 10.1002/acr.24149. [Epub ahead of print]

PMID:
31962005
4.

The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review.

Liem SIE, Vliet Vlieland TPM, Schoones JW, de Vries-Bouwstra JK.

Rheumatol Adv Pract. 2019 Dec 9;3(2):rkz044. doi: 10.1093/rap/rkz044. eCollection 2019. Review.

5.

Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective.

Spierings J, van Rhijn-Brouwer FCC, de Bresser CJM, Mosterman PTM, Pieterse AH, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Kars MC, van Laar JM.

Rheumatology (Oxford). 2019 Dec 6. pii: kez579. doi: 10.1093/rheumatology/kez579. [Epub ahead of print]

PMID:
31808528
6.

Quality of life and strain among caregivers of patients with systemic sclerosis.

Stoop DF, de Vries-Bouwstra JK, Vliet Vlieland TP.

Disabil Rehabil. 2019 Oct 21:1-2. doi: 10.1080/09638288.2019.1674390. [Epub ahead of print] No abstract available.

PMID:
31633430
7.

Cumulative endogenous estrogen exposure is not associated with severity of peripheral microangiopathy in patients with systemic sclerosis.

Ciaffi J, van Leeuwen NM, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):82-87. Epub 2019 Oct 3.

8.

How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?

Spierings J, van den Ende CHM, Schriemer RM, Moens HJB, van der Bijl EA, Bonte-Mineur F, de Buck MPD, de Kanter MAE, Knaapen-Hans HKA, van Laar JM, Mulder UDJ, Potjewijd J, de Pundert LAJ, Schoonbrood THM, Schouffoer AA, Stel AJ, Vercoutere W, Voskuyl AE, de Vries-Bouwstra JK, Vonk MC.

Rheumatology (Oxford). 2019 Sep 20. pii: kez417. doi: 10.1093/rheumatology/kez417. [Epub ahead of print]

PMID:
31539063
9.

Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review.

Ciaffi J, van Leeuwen NM, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK.

Semin Arthritis Rheum. 2020 Feb;50(1):140-148. doi: 10.1016/j.semarthrit.2019.07.007. Epub 2019 Jul 20. Review.

PMID:
31362894
10.

Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients With Systemic Sclerosis.

van Wijngaarden SE, Boonstra M, Bloem B, Cassani D, Tanner FC, Jordan S, Distler O, Delgado V, Bax JJ, de Vries-Bouwstra JK, Ajmone Marsan N.

JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2273-2276. doi: 10.1016/j.jcmg.2019.05.017. Epub 2019 Jul 17. No abstract available.

PMID:
31326475
11.

Degree of Vasculopathy in Systemic Sclerosis Patients with Anti-U3RNP Antibody Indicates Need for Extensive Cardiopulmonary Screening.

VAN Leeuwen NM, Boonstra M, Ajmone Marsan N, Ninaber MK, Huizinga TWJ, DE Vries-Bouwstra JK.

J Rheumatol. 2019 Sep;46(9):1244-1245. doi: 10.3899/jrheum.181378. Epub 2019 Jul 1. No abstract available.

PMID:
31263069
12.

Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis.

de Vries-Bouwstra JK, Allanore Y, Matucci-Cerinic M, Balbir-Gurman A.

J Rheumatol. 2020 Feb;47(2):249-254. doi: 10.3899/jrheum.181173. Epub 2019 May 1.

PMID:
31043545
13.

Living with systemic sclerosis: exploring its impact on caregivers.

Schriemer MR, Spierings J, De Vries-Bouwstra JK, de Pundert LAJ, van den Ende CH, Vonk MC.

Disabil Rehabil. 2019 Apr 30:1-2. doi: 10.1080/09638288.2019.1608320. [Epub ahead of print] No abstract available.

PMID:
31038365
14.

Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Chadli L, Sotthewes B, Li K, Andersen SN, Cahir-McFarland E, Cheung M, Cullen P, Dorjée A, de Vries-Bouwstra JK, Huizinga TWJ, Fischer DF, DeGroot J, Viney JL, Zheng TS, Aarbiou J, Gardet A.

Sci Rep. 2019 Mar 14;9(1):4521. doi: 10.1038/s41598-019-41153-w.

15.

Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study.

van Wijngaarden SE, Ben Said-Bouyeri S, Ninaber MK, Huizinga TWJ, Schalij MJ, Bax JJ, Delgado V, de Vries-Bouwstra JK, Marsan NA.

J Rheumatol. 2019 Apr;46(4):405-415. doi: 10.3899/jrheum.171207. Epub 2019 Mar 1.

PMID:
30824646
16.

Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.

Boonstra M, Ninaber MK, Ajmone Marsan N, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

Rheumatology (Oxford). 2019 Apr 1;58(4):730-732. doi: 10.1093/rheumatology/kez005. No abstract available.

PMID:
30690619
17.

To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?

Boonstra M, Mertens BJA, Bakker JA, Ninaber MK, Ajmone Marsan N, van der Helm-van Mil AHM, Scherer HU, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):109-117. Epub 2018 Jul 18.

PMID:
30148428
18.

A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.

van Rhijn-Brouwer FCC, Gremmels H, Fledderus JO, Schuurman AH, Bonte-Mineur F, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Coert JH, Radstake TRDJ, van Laar JM, Verhaar MC; MANUS Study Group.

BMJ Open. 2018 Aug 20;8(8):e020479. doi: 10.1136/bmjopen-2017-020479.

19.

ECG derived ventricular gradient exceeds echocardiography in the early detection of pulmonary hypertension in scleroderma patients.

Meijer FMM, Kies P, Jongbloed MRM, van Wijngaarden SE, Swenne CA, Man S, Schalij MJ, de Vries-Bouwstra JK, Vliegen HW.

Int J Cardiol. 2018 Dec 15;273:203-206. doi: 10.1016/j.ijcard.2018.07.122. Epub 2018 Jul 24.

PMID:
30097334
20.

A case of late-onset systemic sclerosis with ruptured silicone breast implants.

Meijs J, de Vries-Bouwstra JK, Cohen Tervaert JW, Hoogenberg K.

Neth J Med. 2018 Jul;76(5):243-248. Review.

21.

Physical activity in patients with systemic sclerosis.

Liem SIE, Meessen JMTA, Wolterbeek R, Ajmone Marsan N, Ninaber MK, Vliet Vlieland TPM, de Vries-Bouwstra JK.

Rheumatol Int. 2018 Mar;38(3):443-453. doi: 10.1007/s00296-017-3879-y. Epub 2017 Nov 18.

22.

Rituximab in early systemic sclerosis.

Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

RMD Open. 2017 Jul 28;3(2):e000384. doi: 10.1136/rmdopen-2016-000384. eCollection 2017.

23.

Auto-antibodies and cancer in systemic sclerosis.

Boonstra M, Huizinga TWJ, de Vries-Bouwstra JK.

Autoimmun Rev. 2017 Aug;16(8):883-884. doi: 10.1016/j.autrev.2017.05.023. Epub 2017 May 29. No abstract available.

24.

Lung Density and Pulmonary Artery Diameter are Predictors of Pulmonary Hypertension in Systemic Sclerosis.

Bakker ME, Ninaber MK, Stolk J, Kroft LJM, Schouffoer AA, de Vries Bouwstra JK, van Wijngaarden SE, Stoel BC.

J Thorac Imaging. 2017 Nov;32(6):391-397. doi: 10.1097/RTI.0000000000000279.

PMID:
28549020
25.

Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies.

Markusse IM, Meijs J, de Boer B, Bakker JA, Schippers HPC, Schouffoer AA, Ajmone Marsan N, Kroft LJM, Ninaber MK, Huizinga TWJ, de Vries-Bouwstra JK.

Rheumatology (Oxford). 2017 Jul 1;56(7):1081-1088. doi: 10.1093/rheumatology/kew402.

PMID:
27940596
26.

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis.

Meijs J, Schouffoer AA, Ajmone Marsan N, Kroft LJ, Stijnen T, Ninaber MK, Huizinga TW, Vliet Vlieland TP, de Vries-Bouwstra JK.

RMD Open. 2016 Mar 15;2(1):e000159. doi: 10.1136/rmdopen-2015-000159. eCollection 2016.

27.

A prediction model for progressive disease in systemic sclerosis.

Meijs J, Schouffoer AA, Ajmone Marsan N, Stijnen T, Putter H, Ninaber MK, Huizinga TW, de Vries-Bouwstra JK.

RMD Open. 2015 Dec 1;1(1):e000113. doi: 10.1136/rmdopen-2015-000113. eCollection 2015.

28.

Lung structure and function relation in systemic sclerosis: application of lung densitometry.

Ninaber MK, Stolk J, Smit J, Le Roy EJ, Kroft LJ, Bakker ME, de Vries Bouwstra JK, Schouffoer AA, Staring M, Stoel BC.

Eur J Radiol. 2015 May;84(5):975-9. doi: 10.1016/j.ejrad.2015.01.012. Epub 2015 Jan 22.

PMID:
25650330
29.

Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.

Markusse IM, de Vries-Bouwstra JK, Han KH, van der Lubbe PA, Schouffoer AA, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2014 Sep 25;16(5):430. doi: 10.1186/s13075-014-0430-3.

30.

Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up.

van den Broek M, Dirven L, de Vries-Bouwstra JK, Dehpoor AJ, Goekoop-Ruiterman YP, Gerards AH, Kerstens PJ, Huizinga TW, Lems W, Allaart CF.

Ann Rheum Dis. 2012 Sep;71(9):1530-3. doi: 10.1136/annrheumdis-2011-201212. Epub 2012 Apr 24.

PMID:
22532630
31.

No impact of serum uric acid on the outcome of recent-onset arthritis.

Luczak A, Knevel R, Huizinga TW, van Nies JA, van der Helm-van Mil A, De Vries-Bouwstra JK.

Ann Rheum Dis. 2012 Aug;71(8):1424-5. doi: 10.1136/annrheumdis-2011-201027. Epub 2012 Mar 22. No abstract available.

PMID:
22440824
32.

Diagnostic value of performing chest x-rays in patients presenting with recent-onset arthritis.

de Vries-Bouwstra JK, Huizinga TW, Willems LN, van der Helm-van Mil AH.

Ann Rheum Dis. 2012 Apr;71(4):627-8. doi: 10.1136/annrheumdis-2011-200319. Epub 2011 Nov 21. No abstract available.

PMID:
22110123
33.

Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.

Güler-Yüksel M, Allaart CF, Watt I, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Schaardenburg D, van Krugten MV, Dijkmans BA, Huizinga TW, Lems WF, Kloppenburg M.

Osteoarthritis Cartilage. 2010 Oct;18(10):1256-62. doi: 10.1016/j.joca.2010.07.011. Epub 2010 Aug 5.

34.

A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.

Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2010 Jul;69(7):1333-7. doi: 10.1136/ard.2009.121160. Epub 2010 May 24.

PMID:
20498212
35.

Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.

Güler-Yüksel M, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van der Kooij SM, Gerards AH, Ronday HK, Huizinga TW, Dijkmans BA, Allaart CF, Lems WF.

Arthritis Res Ther. 2010;12(3):R96. doi: 10.1186/ar3025. Epub 2010 May 20.

36.

Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.

Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, Speyer I, de Vries-Bouwstra JK, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2010 Jul;69(7):1342-5. doi: 10.1136/ard.2009.124180. Epub 2010 May 14.

PMID:
20472597
37.

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.

van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, van Zeben D, Hulsmans HM, de Jonge-Bok JM, de Sonnaville PB, Dijkmans BA, Breedveld FC.

Arthritis Rheum. 2009 Mar 15;61(3):291-9. doi: 10.1002/art.24169.

38.

DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis.

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, Speyer I, Seys PE, Breedveld FC, Allaart CF, Dijkmans BA.

Ann Rheum Dis. 2010 Jan;69(1):65-9. doi: 10.1136/ard.2008.097683.

PMID:
19155234
39.

Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.

van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, Kerstens PJ, Peeters AJ, van Zeben D, Breedveld FC, Huizinga TW, Dijkmans BA, Allaart CF.

Arthritis Rheum. 2009 Jan 15;61(1):4-12. doi: 10.1002/art.24367.

40.

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.

van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2009 Jul;68(7):1153-8. doi: 10.1136/ard.2008.093294. Epub 2008 Oct 17.

PMID:
18930988
41.

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.

van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, van der Lubbe PA, de Beus WM, Grillet BA, Ronday HK, Huizinga TW, Breedveld FC, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2009 Jun;68(6):914-21. doi: 10.1136/ard.2008.092254. Epub 2008 Jul 28.

PMID:
18662933
42.

Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.

de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF.

Arthritis Rheum. 2008 May;58(5):1293-8. doi: 10.1002/art.23439.

43.

Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.

Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallée C, de Bois MH, Breedveld FC, Dijkmans BA, Lems WF.

Ann Rheum Dis. 2009 Mar;68(3):330-6. doi: 10.1136/ard.2007.086348. Epub 2008 Mar 28.

PMID:
18375540
44.

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA.

Arthritis Rheum. 2008 Feb;58(2 Suppl):S126-35. doi: 10.1002/art.23364.

45.

Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.

Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-Bouwstra JK, Allaart CF, Drijfhout JW, de Vries RR, Breedveld FC, Huizinga TW, Pruijn GJ, Toes RE.

Arthritis Rheum. 2007 Dec;56(12):3949-52.

46.

Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score.

van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Peeters AJ, van Krugten MV, Breedveld FC, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2008 Feb;67(2):266-9. Epub 2007 Oct 18.

PMID:
17947301
47.

Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.

Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, Han KH, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF.

Ann Rheum Dis. 2008 Jun;67(6):823-8. Epub 2007 Jul 20.

PMID:
17644545
48.

Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis.

van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S, Han KH, van Krugten MV, Allaart CF, Breedveld FC, Dijkmans BA.

Arthritis Rheum. 2007 Jul;56(7):2129-34.

49.

Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis.

Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF.

Ann Rheum Dis. 2007 Nov;66(11):1508-12. Epub 2007 Apr 24.

50.

Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, Han KH, Speyer I, van der Lubbe PA, Seys PE, Breedveld FC, Dijkmans BA.

Ann Rheum Dis. 2007 Sep;66(9):1227-32. Epub 2007 Apr 3.

Supplemental Content

Loading ...
Support Center